European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy

On 21 November 2016, the European Commission issued a marketing authorisation valid throughout the European Union for ixazomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Ixazomib was evalu...

詳細記述

保存先:
書誌詳細
出版年:ESMO Open
主要な著者: Tzogani, Kyriaki, Florez, Beatriz, Markey, Greg, Caleno, Mariapaola, Olimpieri, Odoardo Maria, Melchiorri, Daniela, Hovgaard, Doris Johanna, Sarac, Sinan Bardakci, Penttilä, Karri, Lapveteläinen, Tuomo, Salmonson, Tomas, Bergh, Jonas, Gisselbrecht, Christian, Pignatti, Francesco
フォーマット: Artigo
言語:Inglês
出版事項: BMJ Publishing Group 2019
主題:
Review
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6735670/
https://ncbi.nlm.nih.gov/pubmed/31555488
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000570
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料